Cancer Medicine Approvals in the US

A JAMA cross-sectional study analyzed trends in FDA approvals of cancer medicines for adult solid tumors over a 20-year period from 2006 to 2025, covering both original and supplemental indication approvals. The analysis provides a comprehensive landscape of how the regulatory pipeline for oncology therapeutics has evolved across two decades. The study offers a data-driven overview of approval patterns that may inform policy discussions about drug development efficiency and access to cancer treatments.